DPP-IV Inhibitors and GLP-1 Analogues Will Experience the Biggest Growth in Market Share of All Drug Classes in Type 2 Dia

Merck’s Januvia Will Consolidate Its Position as the Market’s Leading DPP-IV Inhibitor, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of type 2 diabetes, DPP-IV inhibitors and GLP-1 analogues will experience the biggest growth in market share of all drug classes in this indication, with a combined market share that will increase from 20 percent in 2010 to 47 percent in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The findings from the Pharmacor topic entitled Type 2 Diabetes reveal that Merck’s Januvia dominates the DPP-IV inhibitor class and will consolidate its leading position, while other DPP-IV inhibitors will struggle owing to their lack of clinical advantages over Januvia. Additionally, GLP-1 analogues—which have a strong efficacy profile and elicit weight loss—are very popular among thought leaders, who view improved glycemia, weight loss and preservation of beta-cell function in obese type 2 diabetics as landmark progress. The launch of the once-weekly GLP-1 analogue exenatide LAR (Eli Lilly/Amylin/Alkermes’ Bydureon) has been delayed by up to 18 months, giving the once-daily GLP-1 analogue liraglutide (Novo Nordisk’s Victoza) the chance to capitalize on its strong initial uptake.

The overall drug market for type 2 diabetes will nearly double over the next decade, increasing from $23.4 billion in 2010 to almost $45 billion in 2020. The market benefits from a steady increase in the drug-treated patient population and an extensive pipeline of products that are expected to launch between now and 2020.

The findings also reveal that the decision by the U.S. Food and Drug Administration to restrict the availability of GlaxoSmithKline’s Avandia in the United States and a ruling by the European Medicines Agency to withdraw the drug in Europe will cause Avandia to lose almost all its sales, leaving Takeda’s Actos as the predominant representative of the PPAR-gamma agonist drug class on the market. However, concerns about a possible link between Actos and bladder cancer emerged during the first half of 2011.

“These concerns led to Actos being withdrawn in France and Germany and will contribute to a decline in sales in other markets—a decline that will be compounded by the entry of generic Actos, beginning towards the end of 2011,” said Decision Resources Analyst Christine Helliwell, Ph.D. “These safety concerns and generic erosion will lead to a reduction in market share for the PPAR-gamma agonists from 24 percent in 2010 to just 3 percent in 2020.”

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


Decision Resources
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Diabetes  General Health